Shares of Spero Therapeutics Inc (NASDAQ:SPRO) have earned an average recommendation of “Buy” from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $27.33.
Several research firms have commented on SPRO. Cowen reissued a “buy” rating on shares of Spero Therapeutics in a research report on Tuesday, November 5th. Janney Montgomery Scott began coverage on shares of Spero Therapeutics in a research report on Monday, September 9th. They set a “buy” rating on the stock. TheStreet downgraded shares of Spero Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, July 29th. Oppenheimer lowered their target price on shares of Spero Therapeutics from $30.00 to $20.00 in a research report on Wednesday, October 2nd. Finally, HC Wainwright increased their target price on shares of Spero Therapeutics from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th.
Large investors have recently modified their holdings of the company. Acadian Asset Management LLC bought a new stake in shares of Spero Therapeutics in the second quarter valued at about $25,000. Marshall Wace LLP bought a new stake in shares of Spero Therapeutics in the first quarter valued at about $39,000. D.A. Davidson & CO. bought a new stake in shares of Spero Therapeutics in the second quarter valued at about $115,000. Wells Fargo & Company MN lifted its stake in shares of Spero Therapeutics by 187.9% in the second quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock valued at $157,000 after buying an additional 8,915 shares during the period. Finally, Rhumbline Advisers lifted its stake in shares of Spero Therapeutics by 10.9% in the third quarter. Rhumbline Advisers now owns 15,042 shares of the company’s stock valued at $159,000 after buying an additional 1,481 shares during the period. 50.98% of the stock is currently owned by institutional investors.
Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.10). The firm had revenue of $4.64 million for the quarter, compared to analysts’ expectations of $2.03 million. Spero Therapeutics had a negative return on equity of 43.10% and a negative net margin of 287.11%. On average, sell-side analysts forecast that Spero Therapeutics will post -3.11 EPS for the current year.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Featured Story: What is Elliott Wave theory?
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.